Purine derivatives for the treatment of viral infections

Patent metadata

Field	Value
Publication number	US-9556176-B2
Application number	US-201214357495-A
Country	US
Kind code	B2
Filing date	Nov 8, 2012
Priority date	Nov 9, 2011
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

The present invention relates to purine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

First claim

The invention claimed is:

1. A compound of formula (I)

or a pharmaceutically acceptable salt, solvate or polymorph thereof, wherein Y is C 1-4 alkylene,
R 1 is selected from the group consisting of imidazolyl, pyrimidyl, pyrrolyl, pyrazolyl, furyl, oxazolyl, oxadiazolyl, isoxazolyl, pyrazinyl and thiazolyl, wherein R 1 is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, C 1-6 alkyl, C 1-4 alkoxy, trifluoromethyl, C 3-6 cycloalkyl, phenyl, halogen, hydroxyl-C 1-4 alkyl, C 1-4 -alkoxy-C 1-4 -alkyl- and C 1-4 alkyl-diethoxyphosphoryl R 2 is selected from a group consisting of phenyl, naphtyl, anthracenyl and phenanthrenyl, wherein R 2 is optionally substituted by one or more substituents independently selected from the group consisting of hydroxyl, C 1-6 alkyl, C 1-4 alkoxy, trifluoromethyl, CO 2 R 3 , halogen, hydroxyl-C 1-4 alkyl-, NR 6 R 7 , C(O)R 6 , C(O)NR 6 R 7 , C 1-4 alkyl-diethoxyphosphoryl or C 1-4 alkyl-phosphonic acid;
R 3 is selected from H and C 1-6 alkyl;
R 6 and R 7 are each independently selected from H, C 1-6 alkyl or C 1-4 alkoxy—after C 1-4 alkyl-diethoxyphosphoryl.

2. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 1 , together with one or more pharmaceutically acceptable excipients, diluents or carriers.

3. A compound selected from the group consisting of:

4. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof according to claim 3 , together with one or more pharmaceutically acceptable excipients, diluents or carriers.

Assignees

• Janssen R&D Ireland
• Janssen Sciences Ireland Uc

Inventors

• Bonfanti Jean-François
• Doublet Frédéric Marc Maurice
• EMBRECHTS Werner
• Fortin Jérôme Michel Claude
• Mcgowan David Craig
• Muller Philippe
• Raboisson Pierre Jean-Marie Bernard

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/12

  Antivirals · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title